
Real and potential benefits of third-generation calcium antagonists
Author(s) -
А. А. Кириченко
Publication year - 2013
Publication title -
sistemnye gipertenzii
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg28949
Subject(s) - lercanidipine , pharmacokinetics , pharmacology , third generation , calcium , chemistry , angiotensin converting enzyme , medicine , computer science , blood pressure , telecommunications
The paper considers the specific features of the pharmacokinetics of third-generation dihydropyridines (membrane-controlled pharmacokinetics). Comparative trials have shown their longer action and high efficacy, which are highly competitive with those of major groups of antihypertensive drugs. Lercanidipine proved to have the nephroprotective activity comparable with that of angiotensin-converting enzyme (ACE) inhibitors. They have been demonstrated to have a better tolerance and safety than second-generation calcium antagonists.